The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 12, 2021

Filed:

Aug. 07, 2015
Applicant:

Purdue Research Foundation, West Lafayette, IN (US);

Inventors:

Ananda Kumar Kanduluru, West Lafayette, IN (US);

Philip S. Low, West Lafayette, IN (US);

Assignee:

Purdue Research Foundation, West Lafayette, IN (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 49/00 (2006.01); C07K 14/705 (2006.01); C09B 23/01 (2006.01); C09B 11/24 (2006.01); A61K 31/404 (2006.01); A61K 51/04 (2006.01); A61K 31/4545 (2006.01); A61K 31/475 (2006.01); A61K 38/05 (2006.01); A61K 51/06 (2006.01); A61K 51/08 (2006.01);
U.S. Cl.
CPC ...
A61K 49/0052 (2013.01); A61K 31/404 (2013.01); A61K 31/4545 (2013.01); A61K 31/475 (2013.01); A61K 38/05 (2013.01); A61K 49/0041 (2013.01); A61K 51/0455 (2013.01); A61K 51/0459 (2013.01); A61K 51/0478 (2013.01); A61K 51/0482 (2013.01); A61K 51/06 (2013.01); A61K 51/08 (2013.01); C07K 14/70571 (2013.01); C09B 11/24 (2013.01); C09B 23/0025 (2013.01); C09B 23/0066 (2013.01);
Abstract

Neurokinin-1 (NK-1) receptor-binding agent delivery conjugates, compositions comprising NK-1 receptor-binding agent delivery conjugates, and methods for making and administering NK-1 receptor-binding agent delivery conjugates are provided. A conjugate may include an NK-1 receptor-binding moiety, a linker group containing at least one linker selected from the group of a releasable linker and a spacer linker, and an active agent linked to the linker group. The active agent may be selected from the group of fluorophore-containing compounds, radionuclide-containing compounds, and therapeutic agents for treatment of tumor cells characterized by over-expression of the NK-1 receptor.


Find Patent Forward Citations

Loading…